Clinical Trials List
Protocol NumberCAAA617C12301
2021-05-03 - 2026-02-27
Phase III
Recruiting2
ICD-10C61
Malignant neoplasm of prostate
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9185
Malignant neoplasm of prostate
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/19
Investigators and Locations
Co-Principal Investigator
- - - 無
- JIAN-HUA HONG 無
- JHE-CYUAN GUO 無
- Yeong-Shiau Pu 無
- PO-MING CHOW 無
- Yu-Chieh Tsai 無
- YEN-HENG LIN 無
- 劉詩彬 無
- YU-CHUAN LU 無
- Ying-Chun Shen 無
- KUAN-YIN KO 無
- CHUNG-HSIN CHEN 無
- 馮國剛 未分科
- FU-JEN HSUEH 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- I-hung Shao 無
- Yung-Chang Lin 無
- Kung-Chu Ho 無
- Kai-Jie Yu 無
- Yuan-Cheng Chu 無
- Jing-Ren Tseng 無
- 吳俊德 無
- 林柏宏 未分科
- 黃亮鋼 無
- Feng-Yuan Liu 無
- Rita cheng 無
- Hong-Cheng Gan 無
- 黃成之 無
- PO-HUNG LIN 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
35 participants
-
Global
1126 participants
